Sermorelin SMO5 5mg*10vials

Sermorelin SMO5 (5mg x 10 vials) is an upgraded intermediate-potency anabolic growth hormone-releasing hormone (GHRH) fragment research peptide, an improved version of the SMO series, optimized from the basic SMO2. It retains the standard 29 amino acid sequence of natural GHRH activity, fully preserving the original endogenous endocrine activation mechanism and ensuring complete metabolic clearance without hormone accumulation. With optimized molecular biological activity and an upgraded standard 5mg intermediate concentration, SMO5, compared to low-dose SMO2, exhibits stronger GH/IGF-1 axis activation efficiency, more significant anabolic metabolism and tissue repair effects, balancing the authenticity of natural physiology with significant experimental phenotypic differentiation. It is ideal for intermediate-dose gradient efficacy studies, moderate-intensity body composition remodeling, intermediate-potency anti-aging endocrine interventions, and validation of the synergistic mechanism of complex peptides. As a core, mainstream, upgraded research material in the Sermorelin peptide series, SMO5 covers most routine and cutting-edge preclinical endocrine and metabolic research scenarios.

Product Functions and Research Value

In systematic laboratory studies, Sermorelin SMO5 effectively activates the hypothalamic-pituitary-hepatic endocrine axis, triggering stable and high-amplitude physiological pulsatile growth hormone (GH) secretion and continuously and significantly upregulating insulin-like growth factor-1 (IGF-1) levels. It follows the body's natural endocrine negative feedback regulation mechanism, avoiding feedback inhibition and endocrine desensitization caused by exogenous hormones, thereby maintaining long-term homeostasis of pituitary receptors and the endocrine system. Compared to the milder, low-dose version of SMO2, SMO5 comprehensively enhances core physiological activities, including more efficient lean muscle synthesis, deeper activation of systemic fat metabolism, and more significant collagen synthesis and connective tissue repair capabilities. Its core research focuses on moderately improving age-related growth hormone axis dysfunction, moderately optimizing body composition, efficiently repairing tissue damage, moderately regulating sleep endocrine function, and synergistic studies with other growth hormone peptides. SMO5 offers balanced efficacy, low experimental interference, and excellent model tolerability, perfectly addressing the issue of insignificant phenotypic effects in low-dose versions. It provides highly discriminative, reproducible, and realistic physiological data for studies of medium- and high-threshold GHRH pathway mechanisms.

Core Product Advantages

1. SMO5 Intermediate Enhanced Iterative Version: An upgraded version of SMO2, optimizing molecular activity and target binding efficiency. While retaining 100% of the physiological characteristics of natural GHRH, it significantly enhances endocrine activation intensity, filling the research gap between basic low-dose and high-dose extreme interventions.

2. Pure Endogenous Feedback Regulation Mechanism: Utilizing a standard 29-amino acid bioactive fragment, it activates the body's own growth hormone secretion pathway without the need for exogenous hormone supplementation. It protects the integrity of the endocrine feedback loop, effectively preventing long-term receptor desensitization and hormonal imbalance, with physiological simulation accuracy higher than modified peptides.

3. 5mg Balanced Gold Medium Concentration: The classic mainstream medium concentration in the SMO series, balancing experimental safety and phenotypic significance. This product avoids the problems of insufficient efficacy from low-dose products and excessive physiological burden from ultra-high-dose interventions, making it the preferred specification for most routine gradient experiments and complex peptide combination studies. 4. High-purity, low-interference physiological regulation: Precisely targets the GHRH-GH-IGF-1 core pathway with high specificity. It produces effective, moderate-intensity metabolic and anabolistic regulation without interfering with stress hormones such as cortisol and prolactin, ensuring the purity of experimental variables and the reliability of research conclusions. 5. Pharmaceutical-grade quality and standard aseptic packaging: Utilizes advanced aseptic vacuum freeze-drying technology to completely lock in the inherent activity of the peptide. Each batch undergoes rigorous HPLC high-purity testing and comes with a complete official Certificate of Account (COA). The 10-vial integrated aseptic packaging is suitable for medium-sized laboratory research, key endocrinology projects in universities, and global bulk wholesale procurement.

Sermorelin SMO5 5mg*10-vial pack is a medium-potency, advanced synthetic GHRH (growth hormone-releasing hormone) fragment research peptide, and is the mid-range flagship product in this series.